Clovis Oncology Inc. (CLVS)

Business: Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.

IPO Date: 16-Nov-2011

Co-Founder, CEO, Pres & Exec. Director: Mr. Patrick J. Mahaffy MA

Co-Founder, Exec. VP & Chief Regulatory Officer: Dr. Gillian C. Ivers-Read BSc

Listing: NASDAQ: CLVS

Country: United States

Headquarters: Boulder, CO

Website: https://www.clovisoncology.com

Market cap: $246.03 Mln

Revenue (TTM): $144.95 Mln

Earnings (TTM): $-258.42 Mln

Cash: $122.24 Mln

Total Debt: $437.28 Mln

Insider's Holding: 1.44%

Liquidity: Low

52 Week range: $0.58 - 5.92

Shares outstanding: 143,879,008

10 Years Aggregate:

• CFO: $-2,173.19 Mln
• EBITDA: $-2,597.29 Mln
• Net Profit: $-2,769.11 Mln